Follicle-stimulating hormone (FSH) is involved in the regulation and maintenance of gametogenesis. It exists in multiple molecular forms with different oligosaccharide structures which in turn are influenced by the hormonal milieu. Previous studies from our laboratory demonstrated that antiandrogen administration to immature male rats altered the biological activity and the distribution profile of pituitary FSH isoforms. The aim of this study was to examine possible modifications in pituitary FSH polymorphism throughout sexual development (10-, 32- and 75-day-old rats). In addition, the effect of androgen deprivation by castration (32-day-old rats) and its replacement with a nonaromatizable androgen – dihydrotestosterone – on pituitary FSH polymorphism was determined. Concanavalin A affinity chromatography was used to isolate groups of FSH isoforms according to their carbohydrate inner structure. Radioimmunoassay and Sertoli cell bioassay were used to evaluate FSH immuno- and bioactivities. Androgen rise in serum was accompanied by a marked increase in pituitary bio- and immuno-FSH content in 32- and 75-day-old rats. However, FSH pituitary content did not vary despite the significant increment observed in serum FSH levels after castration and decrease to control levels after androgen replacement. The distribution profile of immuno- and bioactive FSH changed throughout sexual maturation. The proportion of pituitary FSH isoforms bearing complex oligosaccharide structures (triantennary, bisecting, complete and truncated biantennary) increased with age, with a concomitant decrease in the proportion of isoforms bearing incomplete carbohydrate chains. The distribution profile observed in castrated 32-day-old rats was similar to that determined in 10-day-old animals. Androgen replacement restored the distribution profile to normal. These results suggest that androgens regulate the incorporation of sugar residues to the carbohydrate chains of pituitary FSH favoring the biosynthesis of complex-type oligosaccharide structures.

1.
Sairam MR, Schiller PW: Receptor binding, biological and immunological properties of chemically deglycosilated pituitary lutropin. Arch Biochem Biophys 1979;197:294–301.
2.
Padmanabhan V, Sairam MR, Hassing JM, Brown MB, Ridings JW, Beitins IZ: Follicle-stimulating hormone signal transduction: Role of carbohydrate in aromatase induction in immature rat Sertoli cells. Mol Cell Endocrinol 1991;79:119–128.
3.
Wide L, Wide M: Higher plasma disappearance rate in the mouse pituitary follicle-stimulating hormone of young women compared to that of men and elderly women. J Clin Endocrinol Metab 1984;58:426–429.
4.
Ulloa-Aguirre A, Espinoza R, Damian-Matsumara P, Chappel SC: Immunological and biological potencies of different molecular species of gonadotrophins. Hum Reprod 1988;3:491–501.
5.
Wide L: Follicle-stimulating hormones in anterior pituitary glands from children and adults differ in relation to sex and age. J Endocrinol 1989;123:519–529.
6.
Padmanabhan V, Mieher CD, Borondi M, I’Anson H, Wood RI, Landefeld TD, Foster DL, Beitins IZ: Circulating bioactive follicle-stimulating hormone and less acidic follicle-stimulating hormone isoforms increase during experimental induction of puberty in the female lamb. Endocrinology 1992;131:213–220.
7.
Ulloa-Aguirre A, Rees Midgley AJ, Beitins IZ, Padmanabhan V: Follicle-stimulating isohormones: Characterization and physiological relevance. Endocr Rev 1995;16:765–787.
8.
Ulloa-Aguirre A, Mejia JJ, Dominguez R, Guevara-Aguirre J, Diaz-Sánchez V, Larrea F: Microheterogeneity of anterior pituitary FSH in the male rat: Isoelectric focusing pattern throughout sexual maturation. J Endocrinol 1986;110:539–549.
9.
Simoni M, Weinbauer GF, Chandolia RK, Nieschlag E: Microheterogeneity of pituitary follicle-stimulating hormone in male rats: Differential effects of the chronic androgen deprivation induced by castration or androgen blockade. J Mol Endocrinol 1992;9:175–182.
10.
Rulli SB, Creus S, Pellizzari E, Cigorraga S, Calandra RS, Campo S: Immunological and biological activities of pituitary FSH isoforms in prepubertal male rats: Effect of antiandrogens. Neuroendocrinology 1996;63:514–521.
11.
Creus S, Pellizzari E, Cigorraga SB, Campo S: Human FSH isoforms: Bio and immunoactivities in post menopause and in normal menstruating women. Clin Endocrinol 1996;44:181–189.
12.
Rulli SB, Gonzalez-Calvar SI, Campo S, Calandra RS: Effects of two nonsteroidal antiandrogens on testicular function in prepubertal rats. J Androl 1995;16:225–232.
13.
Padmanabhan V, Chappel SC, Beitins IZ: An improved in vitro bioassay for follicle-stimulating hormone (FSH) suitable for measurement of FSH in unextracted human serum. Endocrinology 1987;121:1089–1098.
14.
Escobar ME, Rivarola MA, Bergadá C: Plasma concentration of estradiol-17β in premature thelarche and in different types of sexual precocity. Acta Endocrinol 1976;81:351–361.
15.
Ulloa-Aguirre A, Damian-Matsumara P, Espinoza R, Domínguez R, Morales L, Flores A: Effects on neonatal androgenization on the chromatofocusing pattern of anterior pituitary FSH in the female rat. J Endocrinol 1990;126:323–332.
16.
Kornfeld R, Kornfeld S: Assembly of asparagine-linked oligosaccharides. Annu Rev Biochem 1985;54:631–664.
17.
Dharmesh SM, Baenziger JU: Estrogen modulates expression of the glycosyltransferases that synthesize sulfated oligosaccharides on lutropin. Proc Natl Acad Sci USA 1993;90:11127–11131.
18.
Helton TE, Magner JA: Sialyltransferase messenger ribonucleic acid increases in thyrotrophs of hypothyroid mice: An in situ hybridization study. Endocrinology 1994;134:2347–2353.
19.
Helton TE, Magner JA: β-1-,4-Galactosyltransferase and α-mannosidase-II messenger ribonucleic acid levels increase with different kinetics in thyrotrophs of hypothyroid mice. Endocrinology 1994;135:1980–1985.
20.
Arey BJ, Stevis PE, Deecher DC, Shen ES, Frail DE, Negro-Vilar A, Lopez FJ: Induction of promiscuous G protein coupling of the follicle-stimulating hormone (FSH) receptor: A novel mechanism for transducing pleiotropic action of FSH isoforms. Mol Endocr 1997;11:517–526.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.